Remove 2019 Remove Leads Remove Physicians Remove Safety
article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.

article thumbnail

Collaboration with Janssen and Eli Lilly to address lack of paediatric medications

Pharmaceutical Technology

In recent years, with the advent of biologics and novel therapeutic targets such as anti-TNF, anti-interleukin, and anti-integrin, there has been a steady increase in the number of agents approved to treat inflammatory bowel diseases (IBD), which has provided physicians with an increasing number of options to treat Crohn’s disease (CD).

Medical 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cell-based therapies set to become major players in the osteoarthritis market

Pharmaceutical Technology

Invossa has demonstrated the efficacy and safety of a single shot for up to three years, as outlined by Lew in a 2019 study published in Osteoarthritis and Cartilage (NCT03383471). Similarly, ReNu also showed positive efficacy and safety for up to 12 months from a single intra-articular injection (NCT02318511, NCT03063099).

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

of fee-for-service beneficiaries having a type 2 diabetes diagnosis in 2019 , it is among the most widespread chronic conditions in the over-65 population. Unlike in Part D, Part B drugs are physician administered and there is less certainty regarding which drugs will be tapped for negotiations (i.e., With 27.5%

article thumbnail

Patient centricity and the changing pharmaceutical vista

pharmaphorum

Developing medicines – for people living with disease Dr Mullen’s current role involves providing medical monitoring support, as well as safety, pharmacovigilance, scientific, and medical advice across a range of client projects, including advanced therapies and orphan drugs. I still feel that it is very important,” Dr Mullen said.

article thumbnail

Developing new treatment regimens for HIV

European Pharmaceutical Review

Self-stigma is also prevalent and hinders individuals from getting tested, starting pre‑exposure prophylaxis (PrEP) (if they’re HIV negative), seeking the lifesaving treatments they need (if they’re HIV positive), and can lead to isolation and depression.

article thumbnail

Why Are Patients So Angry? Plus, Frontliner Tips for Health Leaders

Healthcare Success

Porath also found that technology overuse leads to increased exposure to negativity and misinformation. And you don’t have to search long to find stories like this: A hospital in Missouri gave their staff panic buttons after hospital staff assaults rose from 40 in 2019 to 123 in 2020—more than a 200% increase. Technology overuse Ms.

Patients 104